The Influences of<i>SLCO1B1</i>and<i>ABCB1</i>Genotypes on the Pharmacokinetics of Simvastatin, in Relation to CYP3A4 Inhibition

Abstract

Only SLCO1B1, not ABCB1 genotype, is likely to be associated with simvastatin-induced myopathy. SLCO1B1 genotyping may be particularly beneficial in simvastatin users who are co-administered CYP3A4 inhibitors.